NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)

CompletedN/A

Sponsor: Pfizer

Conditions: Rheumatoid Arthritis

Interventions: Infliximab [infliximab biosimilar 3]

Countries: Japan

To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against rheumatoid arthritis under actual status of use.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients with rheumatoid arthritis who started treatment with this drug
* Patients who received this drug for the first time after the day of launch of this drug.

Locations (1)

Tokyo, Japan